The
proline-rich antibacterial
peptide Bac7(1-35) protects mice against Salmonella typhimurium
infection, despite its rapid clearance. To overcome this problem the
peptide was linked to a
polyethylene glycol (PEG) molecule either via a cleavable
ester bond or via a non-hydrolysable
amide bond. Both the PEGylated conjugates retained most of the in vitro activity against S. typhimurium. In addition, the
ester bond was cleaved in human serum or plasma, releasing a carboxymethyl derivative of Bac7(1-35) which accounts for a higher activity of this
peptide with relative to the other, non-hydrolysable form. Both PEGylated
peptides maintained the capacity of the unconjugated form to kill bacteria without permeabilizing the bacterial membranes, by penetrating into cells. They exploited the same transporter as unmodified Bac7(1-35), suggesting it has the capacity to internalize quite sizeable cargo if this is linked to
Bac7 fragment. PEGylation allows the
peptide to have a wide distribution in mice, and a slow renal clearance, indicating that this strategy would improve the bioavailability of
Bac7, and in principle of other
antimicrobial peptides. This can be an equally important issue to reducing cytotoxicity for
therapeutic use of these antibacterials.